Meningoencephalitis

Meningoencephalitis is a severe inflammatory condition affecting the central nervous system (CNS), specifically the meninges (pia mater, arachnoid mater, and dura mater) and the underlying brain parenchyma. The term encompasses a spectrum of disorders characterized by inflammation of the leptomeninges and brain tissue, often accompanied by variable degrees of encephalitis, myelitis, and vasculitis. In veterinary medicine, meningoencephalitis is a common neurological emergency that can be caused by infectious agents (viral, bacterial, fungal, parasitic, rickettsial, protozoal) or by non-infectious immune-mediated processes (e.g., meningoencephalitis of unknown origin, MUO). The disease can be classified based on the predominant anatomical location (meningeal vs. parenchymal), the temporal course (peracute, acute, subacute, chronic), the underlying etiology (infectious vs. non-infectious), and the histopathological pattern (e.g., granulomatous, necrotizing, eosinophilic, lymphocytic). Clinically, meningoencephalitis manifests with a combination of systemic signs (fever, lethargy) and neurological deficits (seizures, altered mentation, cranial nerve abnormalities, ataxia, neck pain). Prompt diagnosis and aggressive treatment are critical to minimize irreversible neuronal damage and improve outcomes.

The etiologies of meningoencephalitis are diverse and can be broadly categorized into infectious and non-infectious causes. Infectious agents include: (1) Viral: Canine distemper virus (CDV), rabies virus, parvovirus (in puppies), feline infectious peritonitis virus (FIPV), feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), West Nile virus, pseudorabies virus, and tick-borne encephalitis virus. (2) Bacterial: Staphylococcus spp., Streptococcus spp., Escherichia coli, Pasteurella multocida, Bartonella spp., Listeria monocytogenes, Mycobacterium spp., and anaerobic bacteria. Bacterial meningitis often arises from hematogenous spread, extension from otitis media/interna, or penetrating wounds. (3) Fungal: Cryptococcus neoformans, Blastomyces dermatitidis, Histoplasma capsulatum, Coccidioides immitis, Aspergillus spp., and Candida spp. Fungal infections are more common in immunocompromised animals or those in endemic areas. (4) Parasitic: Toxoplasma gondii, Neospora caninum, Dirofilaria immitis (heartworm), Angiostrongylus cantonensis, Cuterebra spp. larvae, and aberrant larval migrans (Baylisascaris procyonis). (5) Rickettsial: Ehrlichia canis, Anaplasma phagocytophilum, Rickettsia rickettsii (Rocky Mountain spotted fever), and Neorickettsia helminthoeca. (6) Protozoal: Babesia spp., Trypanosoma spp., and Leishmania spp. Non-infectious causes include immune-mediated conditions such as meningoencephalitis of unknown origin (MUO), which encompasses granulomatous meningoencephalomyelitis (GME), necrotizing meningoencephalitis (NME), necrotizing leukoencephalitis (NLE), and eosinophilic meningoencephalitis. These are presumed to be T-cell-mediated autoimmune disorders. Other non-infectious causes include neoplasia (e.g., lymphoma, meningioma), toxins (e.g., lead, organophosphates), and trauma. The specific etiology often dictates the clinical presentation, diagnostic approach, and therapeutic strategy.

Meningoencephalitis occurs in both dogs and cats, with certain breeds and age groups showing increased susceptibility. In dogs, immune-mediated forms (MUO) are more common in young to middle-aged small-breed dogs, particularly Poodles, Maltese, Chihuahuas, Pugs, Yorkshire Terriers, and French Bulldogs. Necrotizing meningoencephalitis (NME) is overrepresented in Pugs, Maltese, and Chihuahuas, while necrotizing leukoencephalitis (NLE) is seen in Yorkshire Terriers and French Bulldogs. Granulomatous meningoencephalomyelitis (GME) has no strong breed predilection but is more common in middle-aged dogs (2-6 years). Infectious causes vary geographically: fungal infections (e.g., cryptococcosis) are more prevalent in the southeastern United States, blastomycosis in the Mississippi River Valley, and coccidioidomycosis in the southwestern US. Tick-borne diseases (ehrlichiosis, anaplasmosis, RMSF) are seasonal and region-dependent. Viral infections like canine distemper are more common in unvaccinated puppies. Feline infectious peritonitis (FIP) is more common in young cats (<2 years) from multi-cat environments. No sex predilection is consistently reported, though some studies suggest a slight female predominance in GME. The incidence of meningoencephalitis is relatively low compared to other neurological disorders, but it carries high morbidity and mortality, making early recognition essential.

The pathophysiology of meningoencephalitis involves a complex interplay between the inciting agent and the host's immune response. Infectious agents can enter the CNS via hematogenous spread (crossing the blood-brain barrier, BBB), direct extension from adjacent structures (e.g., otitis media, sinusitis), or peripheral nerve migration (e.g., rabies virus, pseudorabies). Once in the CNS, pathogens trigger an inflammatory cascade: activation of microglia and astrocytes, release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), recruitment of leukocytes (neutrophils, lymphocytes, macrophages) across the BBB, and disruption of the BBB leading to vasogenic edema. In bacterial meningitis, the release of bacterial toxins and cell wall components (e.g., lipopolysaccharide) further amplifies inflammation, leading to neuronal injury, cerebral edema, and increased intracranial pressure (ICP). Viral infections often cause direct cytolytic damage to neurons and glial cells, as well as immune-mediated demyelination (e.g., canine distemper virus). Fungal and parasitic infections typically induce granulomatous inflammation, with organisms either directly invading tissues or eliciting a chronic T-helper 1 (Th1) response. In immune-mediated forms (MUO), the exact trigger is unknown, but it is hypothesized that molecular mimicry or a dysregulated T-cell response leads to perivascular infiltration of lymphocytes and macrophages, resulting in multifocal or diffuse parenchymal lesions. The inflammatory process can cause necrosis, demyelination, and gliosis, leading to neurological deficits. Secondary complications include cerebral edema, herniation, hydrocephalus, and vasculitis, which can exacerbate ischemia and infarction. The clinical signs reflect the affected neuroanatomical regions, and the severity often correlates with the extent of inflammation and edema.

Several factors predispose animals to meningoencephalitis. Intrinsic factors include: (1) Age: Young animals are more susceptible to infectious causes (e.g., distemper, parvovirus, FIP), while middle-aged dogs are more prone to immune-mediated forms. (2) Breed: Certain breeds have a genetic predisposition to specific forms of MUO (e.g., Pug dog encephalitis, Maltese encephalitis). (3) Immune status: Immunosuppression (e.g., due to corticosteroid therapy, chemotherapy, or concurrent viral infections like FeLV/FIV) increases the risk of opportunistic infections. (4) Genetic factors: Major histocompatibility complex (MHC) polymorphisms may influence susceptibility to autoimmune diseases. Extrinsic factors include: (1) Vaccination status: Incomplete or lack of vaccination increases the risk of viral infections (e.g., distemper, rabies). (2) Geographic location: Endemic areas for fungal and tick-borne diseases increase exposure risk. (3) Environmental exposure: Contact with wildlife (e.g., raccoons for Baylisascaris), contaminated soil, or standing water (for leptospirosis) can introduce pathogens. (4) Management practices: Overcrowding, poor sanitation, and stress can facilitate transmission of infectious agents. (5) Concurrent diseases: Otitis media/interna, sinusitis, or dental disease can serve as a source of bacterial spread to the CNS. (6) Trauma: Penetrating wounds or skull fractures can introduce bacteria directly into the CNS. (7) Medications: Long-term use of immunosuppressive drugs (e.g., cyclosporine, azathioprine) may increase susceptibility to opportunistic infections.

Clinical signs of meningoencephalitis vary depending on the etiology, the affected neuroanatomical regions, and the severity of inflammation. They can be categorized by stage: Peracute: Rapid onset of severe neurological deficits, often within hours, including seizures, stupor, coma, and respiratory depression. Acute: Over 1-3 days, animals may exhibit fever, lethargy, anorexia, neck pain (cervical hyperesthesia), stiff gait, and reluctance to move. Subacute: Progressive signs over 1-2 weeks, including behavioral changes (aggression, depression), circling, head pressing, ataxia, cranial nerve deficits (e.g., facial nerve paralysis, vestibular signs), and proprioceptive deficits. Chronic: Insidious onset over weeks to months, with waxing and waning signs such as mild ataxia, subtle behavior changes, and intermittent neck pain. Terminal: Severe neurological deterioration, including non-ambulatory tetraparesis, decerebrate posturing, and coma. System-by-system manifestations: (1) Musculoskeletal: Neck pain, muscle stiffness, and reluctance to lower the head. (2) Nervous: Seizures (focal or generalized), altered mentation (depression, disorientation, aggression), cranial nerve deficits (anisocoria, strabismus, facial paralysis, deafness), proprioceptive ataxia, paresis or paralysis, and spinal cord signs (if myelitis is present). (3) Ophthalmic: Uveitis, chorioretinitis, optic neuritis (may be seen in infectious and immune-mediated forms). (4) Systemic: Fever, tachycardia, tachypnea, and dehydration. Subtle early indicators include mild lethargy, decreased appetite, and subtle behavioral changes, which may be overlooked by owners. In cats, signs may be more vague, such as hiding, decreased grooming, and altered litter box habits.

Differential diagnoses for meningoencephalitis include: (1) Brain neoplasia (e.g., meningioma, glioma, lymphoma): Can present with similar focal neurological signs and seizures. MRI may show a mass lesion with contrast enhancement; cerebrospinal fluid (CSF) analysis may show increased protein and mixed cell populations, but cytology may be inconclusive. Definitive diagnosis requires histopathology. (2) Cerebrovascular accident (stroke): Acute onset of non-progressive signs, often in older animals with hypertension or hyperadrenocorticism. MRI shows ischemic or hemorrhagic lesions; CSF is often normal or mildly inflammatory. (3) Hydrocephalus: Congenital or acquired, may cause behavioral changes, circling, and visual deficits. Imaging shows ventriculomegaly; CSF may be normal. (4) Toxicity (e.g., lead, ethylene glycol, organophosphates): Acute onset of neurological signs, often with gastrointestinal signs. History of exposure and specific toxicology tests (e.g., blood lead levels) are diagnostic. (5) Metabolic encephalopathies (e.g., hepatic encephalopathy, hypoglycemia, uremia): May cause seizures, depression, and ataxia. Serum biochemistry and bile acid testing help differentiate. (6) Trauma: History of trauma, physical examination findings (e.g., skull fractures), and imaging (CT) can identify hemorrhagic or contusive lesions. (7) Epilepsy (idiopathic): Recurrent seizures with normal interictal neurological examination and normal CSF/imaging. (8) Infectious diseases with systemic signs (e.g., ehrlichiosis, leptospirosis): May have concurrent thrombocytopenia, elevated liver enzymes, and positive serology/PCR. (9) Immune-mediated diseases (e.g., systemic lupus erythematosus): May have polyarthritis, skin lesions, and positive antinuclear antibody (ANA) titers. (10) Degenerative diseases (e.g., degenerative myelopathy): Typically progressive spinal cord signs, but can mimic myelitis. MRI and CSF help differentiate.

The diagnostic approach to meningoencephalitis should be systematic and stepwise: (1) Initial triage: Perform a thorough history and physical examination, including a complete neurological examination. Assess for signs of increased intracranial pressure (ICP) such as stupor, anisocoria, and abnormal respiratory patterns. Stabilize the patient if necessary (e.g., IV fluids, mannitol for cerebral edema). (2) Minimum database: Complete blood count (CBC), serum biochemistry profile, and urinalysis to identify systemic inflammatory or infectious processes. (3) Infectious disease screening: Based on geographic location and exposure history, perform serology or PCR for common infectious agents (e.g., Toxoplasma, Neospora, Cryptococcus, Ehrlichia, Anaplasma, Rickettsia, Bartonella, FeLV/FIV in cats). (4) Advanced imaging: Magnetic resonance imaging (MRI) of the brain is the gold standard for detecting inflammatory lesions. MRI findings may include multifocal T2-hyperintense lesions, contrast enhancement, and meningeal enhancement. Computed tomography (CT) is less sensitive but may be used if MRI is unavailable. (5) Cerebrospinal fluid (CSF) analysis: Perform CSF collection (cerebellomedullary cistern or lumbar) after imaging to rule out increased ICP. CSF analysis should include cell count, protein concentration, cytology, and possibly PCR for infectious agents. Inflammatory CSF (elevated protein, pleocytosis) supports meningoencephalitis. (6) Additional tests: If infectious etiology is suspected, perform specific tests (e.g., fungal culture, bacterial culture and sensitivity, antigen tests for Cryptococcus). If immune-mediated disease is suspected, rule out infectious causes and consider response to immunosuppressive therapy. (7) Histopathology: In cases where antemortem diagnosis is inconclusive or if the patient dies, postmortem examination with histopathology is the definitive diagnostic tool. (8) Genetic testing: For breeds with known genetic predispositions (e.g., Pug dog encephalitis), genetic testing may be available. The diagnostic algorithm should be tailored to the individual patient, balancing the need for rapid diagnosis with the risks of procedures.

Laboratory findings in meningoencephalitis are often non-specific but can provide supportive evidence. Hematology: Complete blood count may reveal leukocytosis (neutrophilia) in bacterial infections, lymphopenia in viral infections, or eosinophilia in parasitic or eosinophilic meningoencephalitis. Thrombocytopenia may be seen in rickettsial diseases (e.g., ehrlichiosis, anaplasmosis). Serum biochemistry: Changes may include elevated liver enzymes (ALT, ALP) in systemic infections or hepatic encephalopathy, hyperglobulinemia in chronic inflammatory or infectious diseases (e.g., FIP, ehrlichiosis), and hypoglycemia in sepsis. Electrolyte disturbances (hyponatremia, hyperkalemia) may occur due to vomiting or renal dysfunction. Urinalysis: May reveal proteinuria, hematuria, or casts in systemic diseases (e.g., leptospirosis). Blood gas analysis: May show metabolic acidosis in severe systemic disease. Specific biomarkers: C-reactive protein (CRP) may be elevated in inflammatory conditions. Serology and PCR: Positive results for specific infectious agents (e.g., Toxoplasma IgG/IgM, Neospora antibodies, Cryptococcus antigen, Ehrlichia PCR) support an infectious etiology. In immune-mediated forms, serology for infectious agents is typically negative. CSF analysis is the most important laboratory test: In bacterial meningitis, CSF typically shows neutrophilic pleocytosis (often >100 cells/µL), elevated protein (>50 mg/dL), and decreased glucose. In viral or immune-mediated meningoencephalitis, CSF may show lymphocytic or mixed pleocytosis (10-100 cells/µL) with mild to moderate protein elevation. Eosinophilic pleocytosis is seen in eosinophilic meningoencephalitis (e.g., due to parasitic migration). CSF culture and sensitivity should be performed if bacterial infection is suspected. PCR on CSF can detect specific pathogens (e.g., Toxoplasma, Neospora, CDV, FIP).

Imaging plays a crucial role in the diagnosis and management of meningoencephalitis. Radiography: Skull radiographs are rarely helpful but may identify fractures, osteomyelitis, or otitis media/interna. Thoracic radiographs may reveal fungal granulomas or metastatic neoplasia. Ultrasonography: Abdominal ultrasound may be useful in detecting systemic infections (e.g., fungal lesions in the spleen or liver) or neoplasia. Computed Tomography (CT): CT of the brain can identify space-occupying lesions, hemorrhage, and hydrocephalus, but is less sensitive than MRI for detecting inflammatory changes. CT may be used for emergency evaluation when MRI is unavailable. Magnetic Resonance Imaging (MRI): MRI is the imaging modality of choice for meningoencephalitis. Typical findings include: (1) T2-weighted and FLAIR hyperintense lesions in the brain parenchyma, often multifocal and asymmetric. (2) Contrast enhancement (gadolinium) of the meninges (leptomeningeal enhancement) and/or parenchymal lesions, indicating BBB disruption. (3) Diffusion-weighted imaging (DWI) may show restricted diffusion in areas of cytotoxic edema (e.g., infarction). (4) In granulomatous meningoencephalomyelitis (GME), lesions may appear as well-defined, contrast-enhancing masses. (5) In necrotizing meningoencephalitis (NME), lesions are often in the cerebral cortex and may show cavitation. (6) In eosinophilic meningoencephalitis, diffuse meningeal enhancement may be seen. MRI also helps rule out other causes (e.g., neoplasia, stroke) and guides CSF collection. Endoscopy: Not directly applicable to the CNS, but bronchoscopy or rhinoscopy may be useful in identifying fungal infections (e.g., aspergillosis) that can spread to the brain. Fluoroscopy: May be used for guided CSF collection in difficult cases. Echocardiography: May be indicated if infective endocarditis is suspected as a source of septic emboli.

Cytology and histopathology are essential for definitive diagnosis of meningoencephalitis. Cerebrospinal fluid (CSF) analysis: CSF cytology is a key diagnostic test. Normal CSF has <5 cells/µL and protein <25 mg/dL. In meningoencephalitis, CSF typically shows pleocytosis (increased cell count) and elevated protein. The cell type can help differentiate etiologies: (1) Neutrophilic pleocytosis: Suggests bacterial meningitis, but can also be seen in early viral or immune-mediated disease. (2) Lymphocytic pleocytosis: Common in viral, rickettsial, and immune-mediated diseases (e.g., GME, NME). (3) Mixed pleocytosis (lymphocytes, monocytes, neutrophils): Seen in many inflammatory conditions. (4) Eosinophilic pleocytosis: Indicates parasitic infection (e.g., Toxocara, Angiostrongylus) or eosinophilic meningoencephalitis. (5) Monocytic/histiocytic pleocytosis: May be seen in fungal infections or GME. Cytology may also reveal infectious organisms (e.g., Cryptococcus yeast, Toxoplasma tachyzoites) or neoplastic cells. Histopathology: Brain biopsy (antemortem) or postmortem examination provides definitive diagnosis. Histopathological findings vary by etiology: (1) Bacterial meningitis: Suppurative inflammation with neutrophils in the meninges and perivascular spaces. (2) Viral encephalitis: Non-suppurative inflammation with perivascular lymphocytic cuffing, neuronal necrosis, and gliosis. (3) Fungal encephalitis: Granulomatous inflammation with fungal organisms visible on special stains (e.g., GMS, PAS). (4) Parasitic encephalitis: Eosinophilic inflammation with parasitic larvae or cysts. (5) GME: Multifocal granulomatous lesions with perivascular accumulation of lymphocytes, plasma cells, and macrophages. (6) NME: Necrotizing lesions with cavitation, predominantly in the cerebral cortex. (7) NLE: Necrotizing lesions in the white matter. Special stains (e.g., immunohistochemistry, PCR) can help identify specific pathogens.

Treatment of meningoencephalitis requires a multi-modal approach tailored to the underlying etiology. Emergency stabilization: If the animal presents with seizures, status epilepticus, or signs of increased ICP, immediate treatment is necessary. Seizures: Administer diazepam (0.5-1 mg/kg IV) or midazolam (0.2-0.3 mg/kg IV) as needed; if refractory, use levetiracetam (20-60 mg/kg IV) or phenobarbital (loading dose 16-20 mg/kg IV, then 2-5 mg/kg q12h). Increased ICP: Administer mannitol (0.5-1 g/kg IV over 15-20 minutes) or hypertonic saline (3-5 mL/kg of 7.5% NaCl IV) to reduce cerebral edema. Fluid therapy: Use isotonic crystalloids (e.g., lactated Ringer's) at maintenance rates (60-100 mL/kg/day in dogs, 40-60 mL/kg/day in cats) to maintain perfusion without exacerbating cerebral edema. Primary medical therapy: (1) Infectious meningoencephalitis: Antibiotics for bacterial infections (e.g., ampicillin 20-40 mg/kg IV q8h, or cefotaxime 50 mg/kg IV q8h, or enrofloxacin 5-10 mg/kg IV q24h) for 4-6 weeks. Antifungals for fungal infections (e.g., fluconazole 5-10 mg/kg PO q12h, or itraconazole 5-10 mg/kg PO q24h) for 6-12 months. Antiparasitics for parasitic infections (e.g., clindamycin 10-20 mg/kg PO q12h for Toxoplasma/Neospora, or fenbendazole 50 mg/kg PO q24h for 5 days for Angiostrongylus). (2) Immune-mediated meningoencephalitis (MUO): Immunosuppressive doses of corticosteroids, e.g., prednisone 1-2 mg/kg PO q12h, tapering over 6-12 months. If inadequate response, add cyclosporine (5-10 mg/kg PO q12h) or cytarabine (50 mg/m² SC q12h for 2 days, repeated every 3 weeks). Supportive care: Provide nutritional support (e.g., feeding tube if anorexic), nursing care (e.g., turning, bladder care), and physical rehabilitation. Surgical intervention: May be indicated for brain abscess drainage or removal of space-occupying lesions (e.g., fungal granuloma). Dietary requirements: High-quality, easily digestible diet; consider omega-3 fatty acids for anti-inflammatory effects. Physical rehabilitation: Passive range-of-motion exercises, assisted standing, and walking to prevent muscle atrophy and contractures.

The prognosis for meningoencephalitis varies widely depending on the etiology, severity of neurological deficits, and timeliness of treatment. Infectious meningoencephalitis: Bacterial meningitis has a guarded prognosis, with mortality rates of 20-50% despite appropriate antibiotics. Viral encephalitis (e.g., distemper) has a poor prognosis, with high mortality and long-term neurological sequelae in survivors. Fungal meningitis (e.g., cryptococcosis) has a fair to good prognosis with prolonged antifungal therapy, but relapse is common. Parasitic meningoencephalitis (e.g., toxoplasmosis) has a good prognosis if treated early. Immune-mediated meningoencephalitis (MUO): The prognosis is variable. GME has a median survival time of 1-2 years with immunosuppressive therapy, but some dogs live longer. NME and NLE have a poorer prognosis, with median survival times of 6-12 months despite treatment. Negative prognostic indicators include: severe neurological deficits (e.g., coma, non-ambulatory status), seizures that are difficult to control, delayed diagnosis, and lack of response to initial therapy. Positive prognostic indicators include: early diagnosis, mild clinical signs, and rapid response to treatment. Mortality rates for MUO are approximately 30-50% within the first year. Recurrence is possible, especially if immunosuppressive therapy is tapered too quickly. Long-term follow-up is essential to monitor for relapse and adjust therapy.

Structured follow-up is crucial for monitoring response to treatment and detecting relapse. Re-check intervals: Initially, re-evaluate the patient every 1-2 weeks during the acute phase. Once stable, re-check every 4-6 weeks for the first 3-6 months, then every 3-6 months thereafter. Serial laboratory monitoring: Perform CBC, serum biochemistry, and urinalysis at each re-check to monitor for drug side effects (e.g., bone marrow suppression with cytarabine, hepatotoxicity with azathioprine). For infectious diseases, repeat serology or PCR to document clearance (e.g., Toxoplasma titers should decrease). For immune-mediated diseases, monitor for signs of immunosuppression (e.g., opportunistic infections). Repeat imaging: MRI may be repeated at 3-6 months to assess resolution of lesions, especially if clinical signs are not improving. CSF analysis may be repeated to document resolution of inflammation. Dose-titration guidelines: For corticosteroids, taper the dose gradually (e.g., decrease by 25% every 2-4 weeks) to the lowest effective dose. If the patient is stable for 6-12 months, consider discontinuing therapy. For other immunosuppressants, adjust based on clinical response and blood levels (e.g., cyclosporine trough levels). Long-term management: Owners should be educated about signs of relapse (e.g., seizures, ataxia, behavior changes) and the importance of compliance with medication. Provide a seizure diary if the patient has seizures. Regular veterinary visits are essential. In cases of infectious meningoencephalitis, ensure completion of the full course of antimicrobial therapy and repeat testing to confirm cure.

Pearls: (1) Always consider meningoencephalitis in any young to middle-aged dog presenting with new-onset seizures, especially if there are multifocal neurological signs or neck pain. (2) MRI is the most sensitive imaging modality; perform it before CSF collection to rule out increased ICP and avoid brain herniation. (3) CSF analysis is essential for diagnosis; even if MRI is normal, CSF may be abnormal. (4) In immune-mediated meningoencephalitis, start immunosuppressive therapy early, but always rule out infectious causes first to avoid exacerbating an infection. (5) Use a combination of corticosteroids and a second immunosuppressant (e.g., cytarabine) for severe or refractory cases. (6) In bacterial meningitis, choose antibiotics that cross the blood-brain barrier (e.g., third-generation cephalosporins, fluoroquinolones) and treat for at least 4-6 weeks. (7) Monitor for increased ICP; signs include bradycardia, hypertension, and abnormal pupillary light reflexes. (8) Provide aggressive supportive care, including nutritional support and nursing care, to improve outcomes. Pitfalls: (1) Performing CSF collection before imaging in a patient with increased ICP can lead to brain herniation and death. (2) Using corticosteroids without ruling out infectious causes can worsen fungal or parasitic infections. (3) Underdosing immunosuppressive therapy or tapering too quickly can lead to relapse. (4) Failing to consider tick-borne diseases in endemic areas can delay appropriate treatment. (5) Overlooking systemic signs (e.g., fever, thrombocytopenia) that may point to an infectious etiology. (6) Not repeating CSF analysis or imaging to confirm resolution of inflammation can lead to premature discontinuation of therapy. (7) Ignoring the importance of long-term follow-up and owner education can result in poor compliance and treatment failure.

Drug protocols are based on Plumb's Veterinary Drug Handbook and current literature. Antimicrobials: (1) Ampicillin: 20-40 mg/kg IV q8h for bacterial meningitis. (2) Cefotaxime: 50 mg/kg IV q8h for bacterial meningitis. (3) Enrofloxacin: 5-10 mg/kg IV or PO q24h (dogs) for susceptible infections; use with caution in cats (5 mg/kg q24h). (4) Doxycycline: 5-10 mg/kg PO q12h for rickettsial diseases (ehrlichiosis, anaplasmosis, RMSF). (5) Clindamycin: 10-20 mg/kg PO q12h for Toxoplasma/Neospora. (6) Fenbendazole: 50 mg/kg PO q24h for 5 days for Angiostrongylus. (7) Fluconazole: 5-10 mg/kg PO q12h for cryptococcosis. (8) Itraconazole: 5-10 mg/kg PO q24h for blastomycosis/histoplasmosis. (9) Amphotericin B: 0.5-1 mg/kg IV q48h (with saline diuresis) for severe fungal infections. Anticonvulsants: (1) Diazepam: 0.5-1 mg/kg IV for acute seizures; may repeat up to 3 times. (2) Levetiracetam: 20-60 mg/kg IV or PO q8h for seizure control. (3) Phenobarbital: Loading dose 16-20 mg/kg IV (dogs) or 10-15 mg/kg IV (cats), then 2-5 mg/kg PO q12h (dogs) or 1.5-2.5 mg/kg PO q12h (cats). Anti-inflammatory/immunosuppressive: (1) Prednisone: 1-2 mg/kg PO q12h for immune-mediated meningoencephalitis; taper over 6-12 months. (2) Cyclosporine: 5-10 mg/kg PO q12h; monitor trough levels (target 400-600 ng/mL). (3) Cytarabine: 50 mg/m² SC q12h for 2 consecutive days, repeated every 3 weeks. (4) Mycophenolate mofetil: 10-20 mg/kg PO q12h (dogs) as an alternative immunosuppressant. (5) Azathioprine: 2 mg/kg PO q24h (dogs) for 7-10 days, then q48h; not recommended in cats. Supportive care: (1) Mannitol: 0.5-1 g/kg IV over 15-20 minutes for increased ICP; repeat if needed. (2) Hypertonic saline (7.5%): 3-5 mL/kg IV over 10-15 minutes. (3) Omeprazole: 0.7-1 mg/kg PO q24h to prevent gastric ulcers if on corticosteroids. (4) Maropitant: 1 mg/kg SC q24h for nausea. Organ-function adjustments: For renal impairment, adjust doses of renally excreted drugs (e.g., enrofloxacin, fluconazole). For hepatic impairment, reduce doses of hepatically metabolized drugs (e.g., phenobarbital, cyclosporine). Contraindications: Avoid corticosteroids in infectious meningoencephalitis unless concurrent inflammation is severe and antimicrobial therapy is adequate. Drug interactions: Fluoroquinolones may interact with theophylline; cyclosporine may interact with ketoconazole (increase cyclosporine levels).

Key clinical trials and consensus guidelines: (1) ACVIM consensus statement on the diagnosis and treatment of immune-mediated meningoencephalitis (2016) recommends a combination of corticosteroids and a second immunosuppressant (e.g., cytarabine) for severe cases. (2) A retrospective study by Lowrie et al. (2013) reported that dogs with GME treated with cytarabine and prednisone had a median survival time of 14 months, compared to 3 months with prednisone alone. (3) A study by Coates et al. (2007) on Pug dog encephalitis (NME) found that a combination of prednisone and levetiracetam improved survival compared to prednisone alone. (4) For bacterial meningitis, a study by Radaelli and Platt (2016) emphasized the importance of early CSF culture and susceptibility testing to guide antibiotic therapy. (5) A meta-analysis by Sturges et al. (2008) on cryptococcal meningitis in cats reported a 70% response rate to fluconazole, with a median survival of 2 years. (6) The ISCAID guidelines for the diagnosis and management of bacterial urinary tract infections (2019) are not directly applicable, but they emphasize the importance of antimicrobial stewardship. (7) A study by Tipold and Schatzberg (2010) on canine distemper encephalitis reported that dogs with non-neurological signs had a better prognosis than those with neurological signs. (8) A prospective study by Windsor et al. (2019) on neosporosis in dogs found that early treatment with clindamycin and ponazuril improved outcomes. (9) The ECVIM consensus on feline infectious peritonitis (2020) recommends antiviral therapy (e.g., GS-441524) for FIP-associated meningoencephalitis, though availability may be limited. (10) A study by Gnirs et al. (2015) on MRI findings in meningoencephalitis of unknown origin reported that multifocal T2-hyperintense lesions with contrast enhancement were the most common findings. These studies support the use of aggressive immunosuppressive therapy for MUO, early and targeted antimicrobial therapy for infectious causes, and the importance of advanced imaging and CSF analysis for diagnosis.